At mdgroup, clinical research is more than a profession — it’s personal. Why We Care is a series of real-life stories from our team, sharing how clinical trials have touched their own lives, families, and communities. These experiences drive our passion for delivering remarkable patient-centric solutions and reinforce why we’re dedicated to making clinical trials more accessible, compassionate, and human.
Every story is a reminder that behind every data point is a person, and behind every treatment breakthrough is hope.
For Jennifer Kinnebrew, paralegal at mdgroup, clinical research became more than a profession when her son, Nathan, was born with a rare eye condition. From a daunting series of diagnoses to navigating the complex world of clinical trials, Jennifer’s journey has given her a profound understanding of what patients and families face. It’s this deeply personal experience that fuels her passion for patient-centric solutions, ensuring no family is left to face rare diseases alone.
My son Nathan was born with extra digits, a detail that initially seemed inconsequential. However, at just four weeks old, we noticed his eyes weren’t focusing properly and moved rapidly, especially when he was upset. By his six-week check-up, he was diagnosed with Congenital Nystagmus—an involuntary, rapid eye movement. Further evaluations revealed Bilateral Optic Nerve Colobomas—holes in his optic nerves—and later, Foveal Hypoplasia and Retinoschisis, affecting his ability to see fine details.
These diagnoses were overwhelming. The uncertainty about his vision and development was daunting. Yet, amidst the challenges, we found hope. Nathan began receiving care at Duke University’s Eye Center and shortly thereafter enrolled in a Natural History Study with National Eye Institute (NEI), where he received testing and care from a team of experts. Their dedicated team has been instrumental in monitoring and supporting his condition, ensuring he receives the best possible care.
Navigating the world of rare diseases often feels isolating. Information is scarce, treatments are limited, and families are left searching for answers. Clinical trials emerge as beacons of hope, offering not only the possibility of new treatments but also a sense of progress and purpose. For families like ours, they represent more than research. They symbolise a chance for a better quality of life.
But participating in clinical trials isn’t straightforward. It involves understanding complex information, managing logistics, and often travelling long distances. The emotional and financial toll can be significant. Living this reality firsthand illuminated the gaps in patient support and the urgent need for more accessible, patient-centric solutions.
My journey with Nathan profoundly influenced my professional path. At mdgroup, we are committed to placing patients at the heart of clinical research. Our mission is to bridge the gap between groundbreaking studies and the patients who need them most. Our goal is to make clinical trials more accessible, manageable, and compassionate, so that hope isn’t hindered by logistical challenges.
Clinical trials are the backbone of medical advancement. They pave the way for new treatments, deepen our understanding of rare conditions, and bring hope to families worldwide. But beyond the data, they are deeply human endeavours—filled with stories of resilience, determination, and love.
As we observe Clinical Trials Day, let’s remember the faces behind the data—the children like my Nathan, the parents navigating uncharted territories, and the professionals dedicated to making a difference.
